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Figure 1. Kaplan Meier survival curve of different magnitudes of serum GM
indices (A), and BAL GM indices (B)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312 S289evaluated the impact of different GM cut-off levels in serum
and BAL on mortality. Kaplan Meier curves were used to
estimate survival, and Cox proportional hazardsmodels were
used to evaluate univariate and adjusted hazards ratios for
180 day all-cause mortality associated with different serum
and BAL GM index cutoff values.
Results: A diagnosis of probable IPA was made by a positive
serumGMindex (0.5) alone in32patients andapositiveBAL
GM index (0.5) alone in47patients. In 21patients, the serum
andBALGMindiceswerebothpositive.Overallmortality in all
patients was 52% at 180 days. Patients with a positive serum
GM index at the time of IPA diagnosis had an increased
mortality (60.4%; n ¼ 53) compared to patients with a nega-
tive serum GM index (42.6%; n ¼ 47). In contrast, a positive
BAL GM index had no effect on mortality (Figure 1A,B). In
addition, the magnitude of the serum GM index was associ-
ated with enhanced mortality. When compared to a serum
GM index of  0.5, increasing values of serum GM were
associated with an increased HR of 180 day mortality (serum
GM  1: HR ¼ 2.18 (1.15-4.15); serum GM  1.5: HR ¼ 2.97
(1.53-5.81); serumGM 2: HR¼ 3.68 (1.63-8.30)). This result
was conﬁrmed in a multivariate analysis that adjusted for
acute GVHD, sex, underlying hematologic disease severity,
and elevated creatinine. No association was seen with
increasing magnitudes of BAL GM indices.
Conclusions: This study shows an increased HR for mortality
with increasing cutoffs of serum GM indices, with no corre-
sponding increase in HR with increasing BAL GM indices. We
propose that the initial serum GM index value at the time of
IPA diagnosis represents both an important prognostic
indicator and a valuable covariate in future analyses on
outcomes in HCT recipients.359
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Background: Phase II studies suggested that pts who
received an in-vivo T-cell depleted (TCD) alloSCT with
Alemtuzumab (AL) tended to have less aGVHD.However, the
utility of this approach is limited by increased incidence ofmixed chimerismwhich is associated with increased disease
recurrence and often require DLI.
Hypothesis:We hypothesize that sub-optimal CD 34 +ve cell
dose contribute to mixed chimerism after an in-vivo TCD
alloSCT using AL. By identiﬁng an optimal CD 34 +ve cell
dose; an in-vivo TCD protocol could maintain the beneﬁt of
lowering the incidences of GVHD and minimize mixed
chimerism. We also evaluate other patient & treatment
characteristics that may contribute to mixed chimerism.
Method: We conducted a retrospective study to evaluate the
impact of CD 34 +ve cell dose and patient and treatment
characteristics on T-cell and Myeloid chimerism after an in-
vivo TCD alloSCT. Between 5/11 & 5/12, 32 consecutive pts
underwent an in-vivo TCD alloSCT. F/M: 18/14. The diagnosis
included 21 AML/MDS, 4 NHL, 3 MDS & 7 others. Conditioning
regimensconsistedofFludarabine/Melphalan:22, Fludarabine/
Busulfan: 7 and others in 3. Upon achievement of engraftment,
wemonitorengraftmentbyShort tandemrepeatmonthlywith
T-cell andMyeloid subsets analysis.We utilize of AL for in-vivo
TCD (20MRD: 30mgonDay -1; 12MUD: 30mgdaily onDay -2
& Day -1). All patients also received cyclosporine.
Results: Pts received a median of 4.96 x 10e6 per kg CD 34
positive cells (range 2.45 e 27.22). 30/32 pts achieved
neutrophils engraftment except 1 died shortly after SCT from
CHF & 1 experienced primary graft failure with day 30 STR
showing only 3% donor T-cell chimerism. On Day 30 post-
SCT, all evaluable pts had predominately donor T-cell
(median 99%; 22/31 (71%)  99%; range 82 to > 99%) and
Myeloid Chimerism (28/31 (90%)  99%. 25 pts survived
beyond Day 90 and have engraftment data available for
analysis . Between Days 90 & 120 analysis, most pts maintain
predominant donor myeloid chimerism (> 95%; median
99%); only 11/25 (44%) had maintained  91% donor T-cell
chimerism. 7/25 (28%) and 7/25 (28%) had 71-90 % and 70%
donor T-cell chimerism respectively. CD 34 +ve Cell dose,
disease type, disease status, prior treatment, age, sources of
stem cells (MRD vs MUD) and conditioning regimen did not
predict for mixed chimerism. While 43% of the patients
received Melphalan/Fludarabine; 60% of the patients
received a busulfan/ﬂudarbine had donor T-cell chimerism
dropped below 80% between day 90-120. Five pts (17%)
developed acute GVHD with only 1 (4%) Grade IV aGVHD.
Conclusion: 1. Mixed chimerism is common after in-vivo
TCD alloSCT; 2. CD 34 Cell dose, disease type, prior treatment,
age, sources of stem cells and conditioning regimen did not
predict for mixed chimerism & 3.The high incidences of
signiﬁcant mixed chimerism (< 80%) on day 90 in pts
received Bu/Flu is of concerns that warrant close monitoring
in future studies.360
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